Article
Immunology
Sergi Casado-Llombart, Maria Velasco-de Andres, Cristina Catala, Alejandra Leyton-Pereira, Rebeca Gutierrez-Cozar, Belen Suarez, Noelia Armiger, Esther Carreras, Miriam Esteller, Elena Ricart, Ingrid Ordas, Javier P. Gisbert, Maria Chaparro, Maria Esteve, Lucia Marquez, David Busquets, Eva Iglesias, Esther Garcia-Planella, Maria Dolores Martin-Arranz, Juliane Lohmann, C. Korcan Ayata, Jan Hendrik Niess, Pablo Engel, Julian Panes, Azucena Salas, Eugeni Domenech, Francisco Lozano
Summary: The expression and variation of CD5 and CD6 may play a role in the pathophysiology of inflammatory bowel diseases, affecting their clinical manifestations and therapeutic requirements.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Ryan W. Gan, Diana Sun, Amanda R. Tatro, Shirley Cohen-Mekelburg, Wyndy L. Wiitala, Ji Zhu, Akbar K. Waljee
Summary: This study replicated a machine-learning model's ability to predict acute exacerbations of inflammatory bowel disease (IBD) in a nationally representative cohort, with the random forest model outperforming the logistic regression model.
Article
Immunology
Huldani Huldani, Ria Margiana, Fawad Ahmad, Maria Jade Catalan Opulencia, Mohammad Javed Ansari, Dmitry Olegovich Bokov, Nargiza N. Abdullaeva, Homayoon Siahmansouri
Summary: Inflammatory bowel disease (IBD) is caused by various pathophysiologic pathways and immune-pathologic etiologies. Mesenchymal Stem Cells (MSCs) have been suggested as a potential treatment for IBD due to their immune regulatory functions. Clinical trials using MSCs from bone marrow, umbilical cord, and adipose tissue have shown promising results in terms of safety. However, further research is needed to obtain more reliable results and more support from laboratory evidence.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Gastroenterology & Hepatology
Gillian Watermeyer, Yaw Awuku, Ernst Fredericks, David Epstein, Mashiko Setshedi, Smita Devani, Wisdom Mudombi, Chris Kassianides, Leolin Katsidzira, Ghassa
Summary: Inflammatory bowel disease (IBD) is possibly underestimated in sub-Saharan Africa due to the high burden of communicable diseases and difficulties in detection. Gastrointestinal infections that resemble IBD can complicate diagnosis and treatment decisions. Constraints in endoscopic capacity and a lack of qualified diagnostic pathologists add to the challenges. Despite high costs and unavailability of medication, cost-effective approaches can be employed to manage IBD in this region.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2022)
Review
Immunology
Hoyul Lee, Jae-Han Jeon, Eun Soo Kim
Summary: Mitochondria play a critical role in regulating immune responses and metabolic reprogramming in inflammation. The metabolic pathways of glycolysis, pyruvate oxidation, and glutaminolysis have been shown to be crucial for the metabolic reprogramming of colitogenic T cells. In addition, mitochondrial dysfunction is implicated in the pathogenesis of inflammatory bowel disease (IBD).
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Angela Saez, Raquel Gomez-Bris, Beatriz Herrero-Fernandez, Claudia Mingorance, Cristina Rius, Jose M. Gonzalez-Granado
Summary: Inflammatory bowel disease (IBD) is a complex condition involving chronic intestinal inflammation and is associated with genetics, environment, immune system, and intestinal barrier function. Recent studies have shown that innate lymphoid cells (ILCs) play crucial roles in intestinal homeostasis and IBD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Pharmacology & Pharmacy
Rocio Rivera Rodriguez, Jeremy James Johnson
Summary: Inflammatory Bowel Disease (IBD) is a chronic autoimmune disease characterized by intestinal inflammation. The incidence of IBD is rapidly increasing in newly developed countries, making it a global concern. Two major types of IBD, ulcerative colitis (UC) and Crohn's disease (CD), have different manifestations and locations of inflammation in the digestive tract. Current FDA-approved treatments for IBD are only effective for 50% of patients and come with serious side effects, highlighting the need for safer and more effective therapies. Plant-based diets, such as the Mediterranean diet rich in anti-inflammatory phytochemicals, have shown benefits in preventing and improving symptoms of IBD. Terpenes, a class of phytochemicals abundant in Mediterranean herbs and citrus fruits, have been studied for their potential to modulate inflammatory signaling in IBD. However, there is still conflicting and inconclusive evidence regarding their effectiveness. This review evaluates preclinical studies on terpenes and their impact on basic inflammatory signaling in IBD.
PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Chemistry, Medicinal
Dandan Liu, Varma Saikam, Katie A. Skrada, Didier Merlin, Suri S. Iyer
Summary: Inflammatory bowel disease (IBD) is a chronic inflammation of the gastrointestinal tract, which can be diagnosed through endoscopy and biopsy. However, these methods are expensive and invasive, so alternative noninvasive biomarkers are being explored for disease management and prognosis.
MEDICINAL RESEARCH REVIEWS
(2022)
Review
Immunology
Diana Coman, Isabelle Coales, Luke B. Roberts, Joana F. Neves
Summary: Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the intestine with a complex etiology involving genetics, gut microbiome, environment, and immune system. Recent research has suggested that innate lymphoid cells (ILCs) may play a significant role in the dysregulation of intestinal immunity observed in IBD. Despite being rare in the intestine, helper-like ILCs may contribute to the exacerbation of IBD pathology.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Gastroenterology & Hepatology
Anna M. Buchner, Yecheskel Schneider, Gary R. Lichtenstein
Summary: Biological therapy targeting tumor necrosis factor-alpha has become crucial in treating patients with inflammatory bowel disease, but high costs limit accessibility. Biosimilars offer the potential to reduce expenditures and increase availability, providing more options for patients.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Immunology
Yaodong Wang, Xiaorong Zhou, Kejian Zou, Guanhua Chen, Ling Huang, Fangying Yang, Wenxu Pan, Hongwei Xu, Zhaohui Xu, Huan Chen, Jiayu Chen, Sitang Gong, Xuan Zhou, Wanfu Xu, Junhong Zhao
Summary: This study revealed that MCT4 exacerbates intestinal inflammation in inflammatory bowel disease by promoting Caspase-1-mediated canonical cell pyroptosis through the ERK1/2-NF-kappa B pathway.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Medicine, Research & Experimental
Chunxiu Yang, Shu-Yuan Xiao
Summary: COVID-19, caused by SARS-CoV-2, can lead to severe complications such as multiple organ failure, with most patients also experiencing gastrointestinal symptoms. Managing these symptoms presents challenges for patients with inflammatory bowel disease (IBD) due to potential interactions between the immune response to COVID-19 and dysregulated immunity associated with IBD.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Immunology
Mobina Jalalvand, Samaneh Enayati, Maryam Akhtari, Elham Madreseh, Ahmadreza Jamshidi, Elham Farhadi, Mahdi Mahmoudi, Aliakbar Amirzargar
Summary: This meta-analysis aimed to determine the frequency of peripheral blood regulatory T cells (Tregs) in inflammatory bowel disease (IBD) patients. The results showed no significant difference in the frequency of PB Tregs between IBD cases and control subjects. However, the frequency of CD4+CD25+CD127- and CD4+CD25+FoxP3+ Tregs were significantly lower in IBD cases. Additionally, UC cases and active IBD cases showed a significantly lower frequency of Treg cells.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Mika Nakayama, Yuki Ozato, Yoshiko Tsuji, Yasuko Arao, Chihiro Otsuka, Yumiko Hamano, Genzo Sumi, Ken Ofusa, Shizuka Uchida, Andrea Vecchione, Hideshi Ishii
Summary: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder characterized by damage to the intestinal mucosa. Recent studies have shown the involvement of RNA modifications in the specific pathogenesis of IBD. RNA modification-targeting reagents have shown promising outcomes in treating colitis. Understanding RNA modifications in IBD could contribute to early diagnosis, disease monitoring, and innovative therapeutic approaches.
Article
Rheumatology
Clare Harris, J. R. Fraser Cummings
Summary: Primary non-response and secondary loss of response are still significant issues with current treatment options for inflammatory bowel disease, highlighting the need for new therapeutic choices. As our understanding of IBD pathogenesis advances, new therapeutic targets are being identified.
Article
Multidisciplinary Sciences
Yoshiyuki Mishima, Shunji Ishihara, Akihiko Oka, Nobuhiko Fukuba, Naoki Oshima, Hiroki Sonoyama, Noritsugu Yamashita, Yasumasa Tada, Ryusaku Kusunoki, Ichiro Moriyama, Takafumi Yuki, Kousaku Kawashima, Yoshikazu Kinoshita
Article
Immunology
Yoshiyuki Mishima, Shunji Ishihara, Md. Monowar Aziz, Akihiko Oka, Ryusaku Kusunoki, Aya Otani, Yasumasa Tada, Yong-Yu Li, Ichiro Moriyama, Naoki Oshima, Takafumi Yuki, Yuji Amano, Satoshi Matsumoto, Yoshikazu Kinoshita
Article
Immunology
Chang Soo Eun, Yoshiyuki Mishima, Steffen Wohlgemuth, Bo Liu, Maureen Bower, Ian M. Carroll, R. Balfour Sartor
INFECTION AND IMMUNITY
(2014)
Article
Gastroenterology & Hepatology
Akihiko Oka, Shunji Ishihara, Yoshiyuki Mishima, Yasumasa Tada, Ryusaku Kusunoki, Nobuhiko Fukuba, Takafumi Yuki, Kousaku Kawashima, Satoshi Matsumoto, Yoshikazu Kinoshita
INFLAMMATORY BOWEL DISEASES
(2014)
Article
Gastroenterology & Hepatology
Ting-Jia Fan, Sandrine Y. Tchaptchet, Diana Arsene, Yoshiyuki Mishima, Bo Liu, R. Balfour Sartor, Ian M. Carroll, Edward A. Miao, Anthony A. Fodor, Jonathan J. Hansen
INFLAMMATORY BOWEL DISEASES
(2018)
Article
Immunology
Taku Kobayashi, Katsuyoshi Matsuoka, Shehzad Z. Sheikh, Steven M. Russo, Yoshiyuki Mishima, Colm Collins, Edwin F. deZoeten, Christopher L. Karp, Jenny P. Y. Ting, R. Balfour Sartor, Scott E. Plevy
JOURNAL OF IMMUNOLOGY
(2012)
Article
Immunology
Erin C. Steinbach, Taku Kobayashi, Steven M. Russo, Shehzad Z. Sheikh, Gregory R. Gipson, Samantha T. Kennedy, Jennifer K. Uno, Yoshiyuki Mishima, Luke B. Borst, Bo Liu, Hans Herfarth, Jenny P. Y. Ting, R. Balfour Sartor, Scott E. Plevy
JOURNAL OF IMMUNOLOGY
(2014)
Article
Medicine, Research & Experimental
Yoshiyuki Mishima, Akihiko Oka, Bo Liu, Jeremy W. Herzog, Chang Soo Eun, Ting-Jia Fan, Emily Bulik-Sullivan, Ian M. Carroll, Jonathan J. Hansen, Liang Chen, Justin E. Wilson, Nancy C. Fisher, Jenny P. Y. Ting, Tomonori Nochi, Angela Wahl, J. Victor Garcia, Christopher L. Karp, R. Balfour Sartor
JOURNAL OF CLINICAL INVESTIGATION
(2019)
Review
Gastroenterology & Hepatology
Yoshiyuki Mishima, Ryan Balfour Sartor
JOURNAL OF GASTROENTEROLOGY
(2020)
Article
Medicine, Research & Experimental
Yoshiyuki Mishima, Hiroki Sonoyama, Shunji Ishihara, Naoki Oshima, Ichiro Moriyama, Kousaku Kawashima, Yoshikazu Kinoshita
LABORATORY INVESTIGATION
(2020)
Review
Biochemistry & Molecular Biology
Yoshiyuki Mishima, Shunji Ishihara
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Review
Biochemistry & Molecular Biology
Yoshiyuki Mishima, Shunji Ishihara
Summary: Irritable bowel syndrome (IBS) is a chronic functional disorder affecting the gastrointestinal tract, with the dysregulation of the brain-gut-microbiome (BGM) axis potentially playing a major role in its pathogenesis. Serotonin is a key neurotransmitter involved in IBS pathology, and genome studies have identified susceptible genes. Treatment strategies targeting 5-HT have shown effectiveness in certain IBS cases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Yoshiyuki Mishima, Bo Liu, Jonathan J. Hansen, R. Balfour Sartor
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2015)